Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.38 +0.6%	$5.30	$1.67 ▼ $7.29	$527.17M	0.94	2.52 million shs	4.67 million shs
FATE Fate Therapeutics	$1.04 -3.7%	$1.12	$0.66 ▼ $4.20	$119.94M	2.24	2.01 million shs	893,376 shs
OPT Opthea	$3.41 +7.2%	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	38,738 shs	3,000 shs
ZVRA Zevra Therapeutics	$9.07 -2.5%	$10.59	$6.19 ▼ $13.16	$509.14M	1.87	758,300 shs	966,453 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+3.48%	+8.08%	+2.10%	+20.77%	+189.19%
FATE Fate Therapeutics	-3.57%	-2.70%	-7.69%	-12.55%	-69.23%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+15.20%
ZVRA Zevra Therapeutics	-0.64%	-2.21%	-13.97%	+9.15%	+28.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.0603 of 5 stars	3.6	1.0	0.0	2.1	1.7	0.6
FATE Fate Therapeutics	3.8807 of 5 stars	3.1	2.0	4.7	1.4	2.5	0.6
OPT Opthea	0.3943 of 5 stars	1.1	0.0	0.0	2.7	0.8	0.6
ZVRA Zevra Therapeutics	3.2435 of 5 stars	4.5	3.0	0.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.17	Buy	$23.25	332.16% Upside
FATE Fate Therapeutics	2.14	Hold	$3.30	217.31% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
ZVRA Zevra Therapeutics	3.00	Buy	$23.71	161.46% Upside

Current Analyst Ratings Breakdown

Latest FATE, ZVRA, OPT, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	ATYR aTyr Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $17.00
8/18/2025	ZVRA Zevra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
8/13/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $18.00
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	$0.76 per share	N/A
FATE Fate Therapeutics	$13.63M	8.80	N/A	N/A	$2.27 per share	0.46
OPT Opthea	$87.67K	5,986.77	N/A	N/A	($0.56) per share	-6.09
ZVRA Zevra Therapeutics	$62.02M	8.21	N/A	N/A	$2.09 per share	4.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.80	N/A	N/A	N/A	N/A	-93.69%	-68.83%	11/6/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.45	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	11/11/2025 (Estimated)
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$0.21	N/A	45.35	N/A	4.33%	-112.40%	-37.67%	11/11/2025 (Estimated)

Latest FATE, ZVRA, OPT, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million
8/7/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	5.63	5.63
FATE Fate Therapeutics	N/A	8.04	8.04
OPT Opthea	N/A	1.57	N/A
ZVRA Zevra Therapeutics	0.52	7.85	7.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
FATE Fate Therapeutics	97.54%
OPT Opthea	55.95%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
FATE Fate Therapeutics	5.51%
OPT Opthea	3.20%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	97.99 million	94.36 million	Optionable
FATE Fate Therapeutics	550	115.33 million	108.98 million	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable
ZVRA Zevra Therapeutics	20	56.14 million	54.79 million	Optionable

FATE, ZVRA, OPT, and ATYR Headlines

Recent News About These Companies

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

August 28 at 7:30 AM | globenewswire.com

Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC

August 26 at 7:38 AM | marketbeat.com

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

August 26 at 7:30 AM | globenewswire.com

Zacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to Hold

August 22, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Sees Strong Trading Volume Following Insider Buying Activity

August 22, 2025 | americanbankingnews.com

Zevra Therapeutics rumor highlighted in Betaville blog

August 21, 2025 | msn.com

Zevra Therapeutics gains amid takeover speculation

August 21, 2025 | msn.com

Zevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 Shares

August 21, 2025 | insidertrades.com

Tourmaline Bio (NASDAQ:TRML) versus Zevra Therapeutics (NASDAQ:ZVRA) Head to Head Review

August 20, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Lower Earnings Estimates for ZVRA

August 17, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZVRA Q3 Earnings

August 17, 2025 | marketbeat.com

Q3 EPS Forecast for Zevra Therapeutics Increased by Analyst

August 17, 2025 | marketbeat.com

HC Wainwright Has Bearish Estimate for ZVRA FY2027 Earnings

August 16, 2025 | marketbeat.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

August 15, 2025 | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down on Analyst Downgrade

August 15, 2025 | marketbeat.com

JMP Securities Lowers Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00

August 15, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPS

August 14, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Altium Capital Management LLC's Largest Position

August 14, 2025 | marketbeat.com

Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability

August 14, 2025 | tipranks.com

Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.

August 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FATE, ZVRA, OPT, and ATYR Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.38 +0.03 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$5.44 +0.06 (+1.12%)

As of 07:52 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Fate Therapeutics NASDAQ:FATE

$1.04 -0.04 (-3.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 +0.00 (+0.48%)

As of 06:46 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 08/28/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Zevra Therapeutics NASDAQ:ZVRA

$9.07 -0.23 (-2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$9.07 0.00 (0.00%)

As of 04:20 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time